Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...

CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received ...

Please provide your email address to receive an email when new articles are posted on . FDA granted approval to darolutamide for metastatic hormone-sensitive prostate cancer. Randomized phase 3 trial ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. The Food and Drug Administration (FDA) ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study in The ...

Feasibility and acceptability of remote activity and patient-reported outcome monitoring in men with prostate cancer undergoing androgen deprivation therapy. Circulating tumor cells and clinical ...

Erleada shows consistent 24-month overall survival in real-world settings and the TITAN trial for metastatic castration-sensitive prostate cancer. Erleada reduces the risk of death by 23% compared to ...

Efficacy and safety of apalutamide in metastatic castration sensitive prostate cancer patients with a prior history of cardiovascular or metabolic risk factors: A post-hoc analysis of the TITAN study.